Streetbeat News

Price Targets

WBS

Piper Sandler analyst Matthew Breese has maintained an Overweight rating on Webster Financial Corporation (NYSE:WBS) and increased the price target from $53 to $60.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 5:04 pm

ZION

Truist Securities analyst Brandon King has reaffirmed a Buy rating on Zions Bancorp (NASDAQ:ZION) and increased the price target from $40 to $51.

Portfolio Pulse from Benzinga Newsdesk

December 15, 2023 | 5:01 pm

WAL

Western Alliance (NYSE:WAL) has received positive analyst ratings in the last quarter, with 8 out of 8 ratings being bullish or somewhat bullish. The average 12-month price target for WAL is $59.38, with a high of $80.00 and a low of $52.00. This target has slightly increased by 0.35% from the previous target of $59.17. Analyst ratings are important as they provide investors with specialized advice on stock performance, although they may be subject to error.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:01 pm

CLX

Analysts have recently updated their ratings for Clorox (NYSE:CLX), with 3 bullish, 7 indifferent, and 5 somewhat bearish ratings in the last quarter. The average 12-month price target among 15 analysts is $137.67, with a high of $162.00 and a low of $117.00. This target is a 5.82% decrease from the previous target of $146.18. Analyst ratings are a tool for investors to gauge stock performance, but they are subject to human error.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

SCHW

Over the past 3 months, 11 Wall Street analysts have provided ratings for Charles Schwab (NYSE:SCHW), with an average 12-month price target of $71.27, a slight decrease from the previous $73.22. The ratings include 1 bullish, 6 somewhat bullish, and 4 indifferent, with no bearish ratings. Analysts' ratings are based on company financials, future earnings predictions, and industry risk.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

CUBE

BMO Capital has upgraded its rating of CubeSmart (NYSE:CUBE) to Outperform with a new price target of $49.00, up from the previous $46.00. CubeSmart's shares are currently trading up 0.99% at $45.92. The new price target suggests a potential upside of 6.71%. CubeSmart is a REIT specializing in self-storage facilities, with a significant presence in Florida, Texas, California, New York, and Illinois, deriving most of its revenue from rental income.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

DIN

Dine Brands Global (NYSE:DIN) has received 7 analyst ratings in the last quarter, with 1 bullish, 4 somewhat bullish, and 2 indifferent. The average price target is $57.57, representing an implied upside from the current price of $50.5. This average price target has decreased by 11.03% from the previous average of $64.71. Analysts rate stocks typically once a quarter and provide forecasts on earnings, revenue, and growth, although their predictions are not infallible.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

CHD

B of A Securities upgraded Church & Dwight Co (NYSE:CHD) to Neutral with a new price target of $100.00, up from $85.00. CHD's shares are currently trading at $91.44, and the new target suggests a potential 9.36% increase. Church & Dwight is a leading producer of baking soda and other consumer products, with over 80% of sales in the U.S.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

BAP

JP Morgan has upgraded its rating of Credicorp (NYSE:BAP) to Overweight with a new price target of $190.00, up from the previous $162.00. Following the upgrade, Credicorp's shares have risen 3.61% to $145.39. The new price target suggests a potential upside of 30.68% from the current share price. Credicorp is a Peruvian financial services company engaged in various banking and insurance activities, as well as investment banking and asset management through its subsidiaries.

Portfolio Pulse from Benzinga Insights

December 15, 2023 | 5:00 pm

CCCC

MRK

C4 Therapeutics, Inc. (NASDAQ:CCCC) stock has surged over 350% in the past five days following positive Phase 1 trial data for CFT7455 in multiple myeloma and an exclusive license and collaboration agreement with Merck & Co Inc (NYSE:MRK). C4 Therapeutics will receive a $10 million upfront payment from Merck. Stifel analyst Bradley Canino upgraded the stock from Hold to Buy and increased the price target from $2 to $12. The trading volume of C4 Therapeutics shares has significantly exceeded the 100-day average.

Portfolio Pulse from Erica Kollmann

December 15, 2023 | 5:00 pm